# A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease

> **NCT06145893** · PHASE3 · RECRUITING · sponsor: **Ganzhou Hemay Pharmaceutical Co., Ltd** · enrollment: 162 (estimated)

## Conditions studied

- Behçet's Disease

## Interventions

- **DRUG:** Hemay005
- **DRUG:** Hemay005
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06145893
- **Lead sponsor:** Ganzhou Hemay Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-13
- **Primary completion:** 2026-05-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06145893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06145893, "A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06145893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*